STRM.BIO utilizes extracellular vesicles to deliver gene therapy, enhancing the efficiency and safety of treatment for patients with rare diseases. This approach aims to simplify the administration of gene therapies, making them more practical and accessible for global patient populations.
Funding
$2.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
NIFounders
Product
Problem
Current gene therapy delivery methods often suffer from limitations in efficiency, safety, and practicality, hindering their widespread use, especially for patients with rare diseases. Traditional approaches can be complex to administer and may not effectively target the necessary cells or tissues, leading to suboptimal therapeutic outcomes.
Solution
STRM.BIO is developing a gene therapy delivery platform based on extracellular vesicles (EVs) to improve the safety, simplicity, and practicality of gene therapies. By leveraging EVs, STRM.BIO aims to enhance targeted delivery of genetic payloads to specific cells, potentially increasing therapeutic efficacy while minimizing off-target effects. This approach seeks to simplify the administration process, making gene therapies more accessible to a broader range of patients globally. The company's technology has the potential to establish a new class of therapeutics for patients in need.
Target Audience
The primary target audience includes patients with rare diseases who could benefit from more effective and accessible gene therapy treatments, as well as the clinicians and researchers who treat and study these conditions.
Features
- Utilizes extracellular vesicles (EVs) for targeted delivery of gene therapies.
- Aims to simplify the administration of gene therapies.
- Designed to improve the safety profile of gene therapy treatments.
- Focuses on enhancing the efficiency of gene delivery to specific cells and tissues.